New study examines real-world switching patterns after patients transition from Humira to biosimilars

Researchers from Truveta have found that adoption of adalimumab biosimilars increased substantially following formulary changes in the United States, though more than one in seven patients who ...

Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, ...

Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?

AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
MarketBeat on MSN

Alvotech nears inflection point with 5 US biosimilars targeted by year-end

Key Points Interested in Alvotech? Here are five stocks we like better. Alvotech says it is at an "inflection point," with management expecting five U.S. biosimilars on the market by year-end after ...
The American Journal of Managed Care

Biosimilars Can Create Huge Savings, but Interchangeability Needs to Be Reviewed

A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability to ...

Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?

Driving revenue growth and earnings growth are two different things.
The American Journal of Managed Care

The Complexities of Biosimilars and the Regulatory Approval Process

Created via the Biologics Price Competition and Innovation Act, the biosimilar class of drugs was conceived as an opportunity to introduce competition for commonly used biologics following loss of ...
STAT

U.S. biologics and biosimilars need distinguishable names

With seven biosimilars currently on the market and 18 biosimilars approved by the FDA as of April 2019, one question is sparking a lot of debate: What should the scientific, or nonproprietary, names ...
STAT

Biosimilars competition helps patients more than generic competition

Much of the current drug-pricing agenda proposed by President Biden and by Congress is based on the belief that greater government control — rather than free market competition — is the best way to ...
pharmaphorum

FDA plan will cut testing requirements for biosimilars

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilars to market, in a bid to accelerate the rollout of cheaper versions of off ...

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA ...
Healthline

My Doctor Prescribed Biosimilars for My IBD: Will They Work?

A doctor or healthcare professional may prescribe medications called biologics to treat inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. These medications have helped ...